Microbiotix Uses SBIR Grant to Develop Screen for Potential Bioterror Pathogen | GenomeWeb
Researchers at Microbiotix are using a three-year Phase I Small Business Innovation Research grant from the National Institutes of Health to develop cell-based screens for compounds that can be used against the bacterium Burkholderia pseudomallei, a company official told CBA News this week.
The company plans to develop reporter screens for four targets from the potentially fatal bacterium, characterize the resulting hits, and develop them into lead compounds, said Donald Moir, CSO of Microbiotix.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.